{"denoms":[{"counts":[{"groupId":"BG000","value":"122"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"243"}],"units":"Participants"}],"groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"BG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"BG001","title":"No Treatment"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.5","value":"61.0"},{"groupId":"BG001","spread":"8.6","value":"62.3"},{"groupId":"BG002","spread":"8.6","value":"61.7"}]}]}],"description":"Age was for the intent-to-treat population (those who received at least one dose of study drug)","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"113"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"130"}],"title":"Male"}]}],"description":"Gender was for the intent-to-treat population (those who received at least one dose of study drug)","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"244"}]}],"title":"Italy"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}